Citius Oncology, Inc. (CTOR)

Citius Oncology Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Selling, General & Admin	18.84	15.65	7.88	2.86
Research & Development	6.64	4.93	4.24	6.86
Operating Expenses	25.48	20.57	12.12	9.71
Operating Income	-25.48	-20.57	-12.12	-9.71
Pretax Income	-25.64	-20.57	-12.12	-9.71
Income Tax Expense	0.94	0.58	0.58	1.15
Net Income	-26.58	-21.15	-12.7	-10.87
Net Income to Common	-26.58	-21.15	-12.7	-10.87
Shares Outstanding (Basic)	71	68	68	34
Shares Outstanding (Diluted)	71	68	68	34
Shares Change (YoY)	5.32%	0.82%	100.00%	-
EPS (Basic)	-0.37	-0.31	-0.19	-0.32
EPS (Diluted)	-0.38	-0.31	-0.19	-0.32
EBIT	-25.48	-20.57	-12.12	-9.71

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q